InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.60
(
-0.22%
)
Bitcoin
65,345.90
(
0.32%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 119065

Friday, 04/29/2011 4:53:48 AM

Friday, April 29, 2011 4:53:48 AM

Post# of 252254

Bimonthly dosing (after the initial loading period) is already the de facto SoC for Lucentis in AMD, and the CATT study produced no data to change this

The ongoing HARBOR trial http://clinicaltrials.gov/ct2/show/NCT00891735 might produce the clinical data for dosing frequency (and perhaps even better efficacy for the higher dose Lucentis).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up